ResearchMoz

The Insurance Industry in the Isle of Man, Key Trends and Opportunities to 2017

Timetric
Published Date » 2013-03-22
No. Of Pages » 92
 Synopsis 
    The report provides in depth market analysis, information and insights into the insurance industry in the Isle of Man, including: 
 
 The Manx insurance industrys growth prospects by insurance segments and categories  
 The competitive landscape in the Manx insurance industry 
 The current trends and drivers of the Isle of Man insurance industry 
 The challenges facing the Isle of Man insurance industry 
 The regulatory framework of the Isle of Man insurance industry 
 
 Summary    
 The Isle of Man is one of the leading offshore financial centers in the world. Business-friendly and transparent regulations coupled with excellent infrastructure have created a thriving business environment on the island. It successfully avoided the effects of the global...
Table of Content

1 Executive Summary

2 Introduction
2.1 What is this Report About?
2.2 Definitions
2.3 Methodology

3 Manx Industry Overview
3.1 Manx Insurance Industry
3.2 Key Industry Trends and Drivers
3.3 Challenges
3.4 Regulation

4 Industry Segmentation
4.1 Life Insurance
4.2 Non-Life Insurance
4.2.1 Property insurance
4.2.2 Motor insurance
4.2.3 Liability insurance
4.2.4 Marine, aviation and transit insurance
4.3 Personal Accident and Health Insurance

5 Competitive Landscape
5.1 Overview
5.2 Leading Companies
5.2.1 Tower Insurance - company overview
5.2.2 Isle of Man Assurance Group (IOMA) - company overview
5.2.3 Zurich International Life Ltd - company overview

6 Macroeconomic Indicators
6.1 GDP at Current Prices (US Dollars)
6.2 GDP per Capita (US dollar)
6.3 Inflation Rate
6.4 Employed Population
6.5 Healthcare Expenditure per Capita
6.6 Healthcare Expenditure as Percentage of GDP
6.7 Total Number of Air Passenger
6.8 Total Population

7 Appendix
7.1 Methodology
7.2 Contact Us
7.3 About Timetric
7.4 Disclaimer

List of Tables


Table 1: Insurance Industry Definitions
Table 2: Manx Insurance Industry - Overall Written Premium by Segment (GBP Billion),
Table 3: Manx Insurance Industry - Overall Written Premium by Segment (US$ Billion),
Table 4: Manx Insurance Industry - Overall Written Premium by Segment (GBP Billion),
Table 5: Manx Insurance Industry - Overall Written Premium by Segment (US$ Billion),
Table 6: Manx Insurance Industry - Segmentation (% Share), 2008-2017
Table 7: Manx Life Insurance - Gross Written Premium (GBP Billion), 2008-2012
Table 8: Manx Life Insurance - Paid Claims (GBP Billion), 2012-2017
Table 9: Manx Life Insurance - Paid Claims (GBP Billion), 2008-2012
Table 10: Manx Life Insurance - Paid Claims (GBP Billion), 2012-2017
Table 11: Manx Life Insurance - Incurred Loss (GBP Billion), 2008-2012
Table 12: Manx Life Insurance - Incurred Loss (GBP Billion), 2012-2017
Table 13: Manx Life Insurance - Loss Ratio (%), 2008-2012
Table 14: Manx Life Insurance - Loss Ratio (%), 2012-2017
Table 15: Manx Life Insurance - Combined Ratio (%), 2008-2012
Table 16: Manx Life Insurance - Combined Ratio (%), 2012-2017
Table 17: Manx Life Insurance - Total Assets (GBP Billion), 2008-2012
Table 18: Manx Life Insurance - Total Assets (GBP Billion), 2012-2017
Table 19: Manx Life Insurance - Total Investment Income (GBP Billion), 2008-2012
Table 20: Manx Life Insurance - Total Investment Income (GBP Billion), 2012-2017
Table 21: Manx Life Insurance - Retentions (GBP Billion), 2008-2012
Table 22: Manx Life Insurance - Retentions (GBP Billion), 2012-2017
Table 23: Manx Non-Life Insurance Written Premium by Category (GBP Billion), 2008-2012
Table 24: Manx Non-Life Insurance Written Premium by Category (US$ Billion), 2008-2012
Table 25: Manx Non-Life Insurance Written Premium by Category (GBP Billion), 2012-2017
Table 26: Manx Non-Life Insurance Written Premium by Category (US$ Billion), 2012-2017
Table 27: Manx Non-Life Insurance - Paid Claims (GBP Billion), 2008-2012
Table 28: Manx Non-Life Insurance - Paid Claims (GBP Billion), 2012-2017
Table 29: Manx Non-Life Insurance - Incurred Loss (GBP Billion), 2008-2012
Table 30: Manx Non-Life Insurance - Incurred Loss (GBP Billion), 2012-2017
Table 31: Manx Non-Life Insurance - Loss Ratio (%), 2008-2012
Table 32: Manx Non-Life Insurance - Loss Ratio (%), 2012-2017
Table 33: Manx Non-Life Insurance - Combined Ratio (%), 2008-2012
Table 34: Manx Non-Life Insurance - Combined Ratio (%), 2012-2017
Table 35: Manx Non-Life Insurance - Total Assets (GBP Billion), 2008-2012
Table 36: Manx Non-Life Insurance - Total Assets (GBP Billion), 2012-2017
Table 37: Manx Non-Life Insurance - Retentions (GBP Billion), 2008-2012
Table 38: Manx Non-Life Insurance - Retentions (GBP Billion), 2012-2017
Table 39: Manx Property Insurance - Written Premium (GBP Billion), 2008-2012
Table 40: Manx Property Insurance - Written Premium (GBP Billion), 2012-2017
Table 41: Manx Motor Insurance - Written Premium (GBP Billion), 2008-2012
Table 42: Manx Motor Insurance - Written Premium (GBP Billion), 2012-2017
Table 43: Manx Liability Insurance - Written Premium (GBP Billion), 2008-2012
Table 44: Manx Liability Insurance - Written Premium (GBP Billion), 2012-2017
Table 45: Manx Marine, Aviation and Transit Insurance - Written Premium (GBP Billion), 2008-2012
Table 46: Manx Marine, Aviation and Transit Insurance - Written Premium (GBP Billion), 2012-2017
Table 47: Manx Personal Accident and Health Insurance - Written Premium (GBP Billion), 2008-2012
Table 48: Manx Personal Accident and Health Insurance - Written Premium (GBP Billion), 2012-2017
Table 49: Manx Personal Accident and Health Insurance - Paid Claim (GBP Billion), 2008-2012
Table 50: Manx Personal Accident and Health Insurance - Paid Claim (GBP Billion), 2012-2017
Table 51: Manx Personal Accident and Health Insurance - Incurred Loss (GBP Billion), 2008-2012
Table 52: Manx Personal Accident and Health Insurance - Incurred Loss (GBP Billion), 2012-2017
Table 53: Manx Personal Accident and Health Insurance - Loss Ratio (%), 2008-2012
Table 54: Manx Personal Accident and Health Insurance - Loss Ratio (%), 2012-2017
Table 55: Manx Personal Accident and Health Insurance - Combined Ratio (%), 2008-2012
Table 56: Manx Personal Accident and Health Insurance - Combined Ratio (%), 2012-2017
Table 57: Manx Personal Accident and Health Insurance - Total Assets (GBP Billion), 2008-2012
Table 58: Manx Personal Accident and Health Insurance - Total Assets (GBP Billion), 2012-2017
Table 59: Manx Personal Accident and Health Insurance - Retentions (GBP Billion), 2008-2012
Table 60: Manx Personal Accident and Health Insurance - Retentions (GBP Billion), 2012-2017
Table 61: Manx Insurance Industry Registered Entities 2008-2012
Table 62: Tower Insurance, Main Products
Table 63: Tower Insurance, Key Employees
Table 64: Isle of Man Assurance Group (IOMA), Main Products
Table 65: Isle of Man Assurance Group (IOMA), Key Employees
Table 66: Zurich International Life Ltd, Main Products
Table 67: Zurich International Life Ltd, Key Employees

List of Figures


Figure 1: Manx Insurance Industry – Overall Written Premium by Segment (GBP Billion),
Figure 2: Manx Insurance Industry – Dynamics by Segment, 2008–2017
Figure 3: Manx Life Insurance – Gross Written Premium (GBP Billion), 2008–2012
Figure 4: Manx Life Insurance – Paid Claims (GBP Billion), 2012–2017
Figure 5: Manx Life Insurance – Paid Claims (GBP Billion), 2008–2012
Figure 6: Manx Life Insurance – Paid Claims (GBP Billion), 2012–2017
Figure 7: Manx Life Insurance – Incurred Loss (GBP Billion), 2008–2012
Figure 8: Manx Life Insurance – Incurred Loss (GBP Billion), 2012–2017
Figure 9: Manx Life Insurance – Loss Ratio (%), 2008–2012
Figure 10: Manx Life Insurance – Loss Ratio (%), 2012–2017
Figure 11: Manx Life Insurance – Combined Ratio (%), 2008–2012
Figure 12: Manx Life Insurance – Combined Ratio (%), 2012–2017
Figure 13: Manx Life Insurance – Total Assets (GBP Billion), 2008–2012
Figure 14: Manx Life Insurance – Total Assets (GBP Billion), 2012–2017
Figure 15: Manx Life Insurance – Total Investment Income (GBP Billion), 2008–2012
Figure 16: Manx Life Insurance – Total Investment Income (GBP Billion), 2012–2017
Figure 17: Manx Life Insurance – Retentions (GBP Billion), 2008–2012
Figure 18: Manx Life Insurance – Retentions (GBP Billion), 2012–2017
Figure 19: Manx Life Insurance – Investment (GBP Billion), 2008–2012
Figure 20: Manx Non-Life Insurance Written Premium by Category (GBP Billion), 2008–2017
Figure 21: Manx Non-Life Insurance Written Premium by Category (% Share), 2012 and 2017
Figure 22: Manx Non-Life Insurance Industry Dynamics by Category, 2008–2017
Figure 23: Manx Non-Life Insurance – Paid Claims (GBP Billion), 2008–2012
Figure 24: Manx Non-Life Insurance – Paid Claims (GBP Billion), 2012–2017
Figure 25: Manx Non-Life Insurance – Incurred Loss (GBP Billion), 2008–2012
Figure 26: Manx Non-Life Insurance – Incurred Loss by Category (GBP Billion), 2012–2017
Figure 27: Manx Non-Life Insurance – Loss Ratio (%), 2008–2012
Figure 28: Manx Non-Life Insurance – Loss Ratio (%), 2012–2017
Figure 29: Manx Non-Life Insurance – Combined Ratio (%), 2008–2012
Figure 30: Manx Non-Life Insurance – Combined Ratio (%), 2012–2017
Figure 31: Manx Non-Life Insurance – Total Assets (GBP Billion), 2008–2012
Figure 32: Manx Non-Life Insurance – Total Assets (GBP Billion), 2012–2017
Figure 33: Manx Non-Life Insurance – Retentions (GBP Billion), 2008–2012
Figure 34: Manx Non-Life Insurance – Retentions (US$ Billion), 2012–2017
Figure 35: Manx Property Insurance – Written Premium (GBP Billion), 2008–2012
Figure 36: Manx Property Insurance – Written Premium (GBP Billion), 2012–2017
Figure 37: Manx Motor Insurance – Written Premium (GBP Billion), 2008–2012
Figure 38: Manx Motor Insurance – Written Premium (GBP Billion), 2012–2017
Figure 39: Manx Liability Insurance – Written Premium (GBP Billion), 2008–2012
Figure 40: Manx Liability Insurance – Written Premium (GBP Billion), 2012–2017
Figure 41: Manx Marine, Aviation and Transit Insurance – Written Premium (GBP Billion), 2008–2012
Figure 42: Manx Marine, Aviation and Transit Insurance – Written Premium (GBP Billion), 2012–2017
Figure 43: Manx Personal Accident and Health Insurance – Written Premium (GBP Billion), 2008–2012
Figure 44: Manx Personal Accident and Health Insurance – Written Premium (GBP Billion), 2012–2017
Figure 45: Manx Personal Accident and Health Insurance – Paid Claims by Category (GBP Billion), 2008–2012
Figure 46: Manx Personal Accident and Health Insurance – Paid Claims (GBP Billion), 2012–2017
Figure 47: Manx Personal Accident and Health Insurance – Incurred Loss (GBP Billion), 2008–2012
Figure 48: Manx Personal Accident and Health Insurance – Incurred Loss by Category (GBP Billion), 2012–2017
Figure 49: Manx Personal Accident and Health Insurance – Loss Ratio (%), 2008–2012
Figure 50: Manx Personal Accident and Health Insurance – Loss Ratio (%), 2012–2017
Figure 51: Manx Personal Accident and Health Insurance – Combined Ratio (%), 2008–2012
Figure 52: Manx Personal Accident and Health Insurance – Combined Ratio (%), 2012–2017
Figure 53: Manx Personal Accident and Health Insurance – Total Assets (GBP Billion), 2008–2012
Figure 54: Manx Personal Accident and Health Insurance – Total Assets (GBP Billion), 2012–2017
Figure 55: Manx Personal Accident and Health Insurance – Retentions (GBP Billion), 2008–2012
Figure 56: Manx Personal Accident and Health Insurance – Retentions (US$ Billion), 2012–2017
Figure 57: Manx GDP at Current Prices (US$ Billion), 2007–2011
Figure 58: Manx GDP Per Capita (US$ ’000), 2007–2011
Figure 59: Manx Inflation Rate (%), 2007–2011
Figure 60: Manx Employed Population, 2007–2011
Figure 61: Manx Healthcare Expenditure Per Capita (US$), 2007–2011
Figure 62: Manx Healthcare Expenditure as percentage of GDP 2007–2011
Figure 63: Total Number of Air Passenger (in ‘000), 2007–2011
Figure 64: Manx Total Population (in Million), 2007–2011

Upcoming Reports:

DNA Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
The completion of human genome project resulted in discovery of several human disease causing genes. This discovery has further led to the evolution of DNA diagnostic platforms and resulted in the transformation of DNA diagnostics platforms from a research based activity into a major professional or commercial activity. The transformation is majorly attributed to the rapid pace of technological advances followed by development of robust methodologies such as polymerase chain reaction (PCR), microarrays, novel gene sequencing and others. DNA based diagnostic methods facilitate the...
Antiknock Agents Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
By - Transparency Market Research
Antiknock agent is a gasoline additive that works to reduce the engine knocking tendency while trying to accelerate the octane rating of the fuel. Mixture of gas and air in a conventional car engine has a problem with igniting too early and when this happens, it creates a knocking noise.  Commonly used antiknock agents are tetraethyl lead, ferrocene, toluene, iron pentacarbonyl, isooctane and methylcyclopentadienyl manganese tricarbonyl. Lead compounds have been used as an antiknock agent for many years. The most commonly used is tetraethyl lead, a transparent and highly...
Poland: fermented beverages market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the fermented beverages market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the fermented beverages market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Nuclear Development Plans in China Gets Fresh Impetus
Mar 5, 2015  
The nuclear development plans of China got a renewed momentum on Wednesday as State Council gave a nod to build new reactors at the nuclear power plant located near Hongyan River. The unit 5 and 6 of the nuclear plant near Hongyan River, located in the northeastern province of Liaoning got approval for construction from the State Council. The council also mentioned that the construction should...
Indian Telecoms Bid at Spectrum War
Mar 5, 2015  
The Indian government on Wednesday managed to mop up nearly INR 60,000 crore with the spectrum auctions off to a wonderful start. Top bidders included Idea Cellular, Bharti Airtel, and Vodafone India who fought tooth and nail to gain secure airwaves in those areas where their licenses were nearing expiration. Reliance Jio Infocomm made a strenuous attempt to acquire as many data airwaves as...
South Korean Pharmaceutical Companies Extend Business with Saudi Arabia
Mar 5, 2015  
Four South Korean pharmaceutical companies will export their products to Saudi Arabia, including anticancer drugs and antibiotics, for the coming five years, South Korea’s Health Ministry informed this Wednesday, as a result of South Korean President Park Geun-hye's business trip to the Saudi Arabia this week. Ascertaining to the export agreement, representatives of these four Korean...
U.K. Government Slow to Stop Pharma R&D Slump
Mar 4, 2015  
When it comes to turnaround strategies, the focal point of the U.K. government is currently the life sciences industry. Recent data however shows that healthcare companies are spending less and less on research and development processes on drugs in the country. The Office of National Statistics released the data earlier this week. It shows the United Kingdom’s drug production...
Sun Pharma Buys Out GSK Australian Opiates Business
Mar 4, 2015  
Global pharmaceutical giant GSK announced on Tuesday that they had come to an agreement with Sun Pharmaceuticals Industries for the latter to buy out the opiates business in Australia owned by GSK. A joint statement was made by the two pharma top companies. The statement said that the companies’ respective wholly owned subsidiaries had already come to an agreement that was...